{"filing":{"accession_number":"0001730430-26-000034","cik":"0001730430","ticker":"KNSA","company_name":"Kiniksa Pharmaceuticals International, plc","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-17","primary_document":"knsa-20261017x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730430/000173043026000034/knsa-20261017x8k.htm"},"events":[{"id":37281,"run_id":34370,"accession_number":"0001730430-26-000034","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses the appointment of Ross Moat as President and Chief Operating Officer effective immediately on October 17, 2026. While the disclosure also includes compensation adjustments (salary increase from $650,000 to $700,000 and bonus target increase from 55% to 60%), the principal action is the promotion to a new executive title. The appointment of an officer to a senior C-suite role is material to investors assessing company leadership and governance.","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41940,"accession_number":"0001730430-26-000034","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Ross Moat as President and Chief Operating Officer effective immediately on October 17, 2026. While the disclosure also includes compensation adjustments (salary increase from $650,000 to $700,000 and bonus target increase from 55% to 60%), the principal action is the promotion to a new executive title. The appointment of an officer to a senior C-suite role is material to investors assessing company leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:29:44.567726+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41940,"accession_number":"0001730430-26-000034","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the appointment of Ross Moat as President and Chief Operating Officer effective immediately on October 17, 2026. While the disclosure also includes compensation adjustments (salary increase from $650,000 to $700,000 and bonus target increase from 55% to 60%), the principal action is the promotion to a new executive title. The appointment of an officer to a senior C-suite role is material to investors assessing company leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:29:44.567726+00:00","company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","filing_date":"2026-10-22"}]}